Arrowhead Pharmaceuticals Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
Did you know?
Capital expenditures decreased by 84% from FY24 to FY25.
Current Price
$74.81
+1.81%Profile
Valuation (TTM)
Market Cap$10.16B
P/E50.23
EV—
P/B21.80
Shares Out135.81M
P/Sales9.31
Revenue$1.09B
EV/EBITDA29.30
Arrowhead Pharmaceuticals Inc (ARWR) Stock News
ARWR Stock News & Headlines
Latest stock news and headlines for Arrowhead Pharmaceuticals Inc (ARWR). Stay informed on earnings reports, analyst upgrades and downgrades, market-moving events, and company announcements.
Current stock price: $74.81. Market cap: $10.16B. Sector: Healthcare. Industry: Biotechnology. This page aggregates the latest news articles relevant to ARWR from financial news sources, helping investors stay current on events that may impact Arrowhead Pharmaceuticals Inc's stock price.
News catalysts can drive significant short-term price movement. Earnings surprises, management changes, product launches, regulatory decisions, and analyst coverage changes all create opportunities and risks. Combine news monitoring with GoodMoat's fundamental analysis, quality scores, and valuation tools for a complete research workflow on Arrowhead Pharmaceuticals Inc (ARWR).